Non-Small Cell Lung Cancer (NSCLC)

Protocol AMP-024

AMP-024 is a single arm Phase II study to assess the efficacy of the combination of Amplimexon® with Taxotere® (docetaxel) in patients with previously treated NSCLC.  It is currently under development.  Further information on this protocol will be available in the near future.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Further information

For more information on AMP-024 or to find the clinical trial site nearest you, please click here.